

From: [Stephanie Kennedy](#)
To: [Pharmacy Services](#)
Subject: Written Testimony
Date: Wednesday, December 9, 2020 8:49:36 AM
Attachments: [image001.png](#)

Attached is written testimony for Epidiolex. Effective, 7-31-20, the FDA approved EPIDIOLEX® (cannabidiol) for the treatment of seizures associated with Tuberous Sclerosis Complex (TSC) in patients 1 year of age and older. This is the third indication approved for EPIDIOLEX. In addition, the FDA also approved changes to the age limit for our other two indications (seizures associated with Lennox-Gastaut and Dravet Syndromes) from 2 years to 1 year of age.

Thank you for your time!

Best,

Stephanie

Stephanie Kennedy, PharmD, MBA

Health Outcomes Liaison Manager

(602)909-5361 cell

5750 Fleet Street, Suite 200, Carlsbad, CA 92008

www.greenwichbiosciences.com



PLEASE READ: This email is confidential and may be privileged. It is intended for the named addressee(s) only and access to it by anyone else is unauthorised. If you are not an addressee, any disclosure or copying of the contents of this email or any action taken (or not taken) in reliance on it is unauthorised and may be unlawful. If you have received this email in error, please notify the sender or postmaster@gwpharm.com Email is not a secure method of communication and the Company cannot accept responsibility for the accuracy or completeness of this message or any attachment(s). Please check this email for virus infection for which the Company accepts no responsibility. If verification of this email is sought then please request a hard copy. Unless otherwise stated, any views or opinions presented are solely those of the author and do not represent those of the Company.
